FDA Accepts Dapagliflozin Application from Centaur Pharmaceuticals
The FDA has accepted the application ANDA220679 for dapagliflozin from Centaur Pharmaceuticals.
Company
Centaur Pharmaceuticals
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's acceptance of Centaur Pharmaceuticals' application for dapagliflozin marks a significant entry into the SGLT2 inhibitor market, intensifying competition among existing players. Portfolio teams must evaluate the implications for market share and competitive dynamics as the application progresses through the review process.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the progress of the application review and any subsequent approval timelines.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.